Clinical Trial Update: Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial of S241656 in RAS/MAPK mutation-positive malignancies is currently recruiting. The study targets non-small cell lung cancer and other h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Colorectal Cancer
• Histiocytic Neoplasm
• Histiocytosis
• Non-small Cell Lung Cancer
• Thyroid Cancer

Drugs mentioned

• S241656

Snippet

Sponsor: Institut de Recherches Internationales Servier | Conditions: Non-small Cell Lung Cancer, Histiocytic Neoplasm | Phase 1, Phase 2 | Status: RECRUITING